These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 25361983)
21. HRCT features distinguishing pre-invasive from invasive pulmonary adenocarcinomas appearing as ground-glass nodules. Zhang Y; Shen Y; Qiang JW; Ye JD; Zhang J; Zhao RY Eur Radiol; 2016 Sep; 26(9):2921-8. PubMed ID: 26662263 [TBL] [Abstract][Full Text] [Related]
22. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530 [TBL] [Abstract][Full Text] [Related]
23. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status. Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073 [TBL] [Abstract][Full Text] [Related]
24. [Growth Regularity of Pulmonary Ground Glass Nodules Based on 3D Reconstruction Technology]. Zhou Y; Zhang Y; Zhang S; Zhang C; Chen Z Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):265-273. PubMed ID: 37183641 [TBL] [Abstract][Full Text] [Related]
25. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. Sakamoto H; Shimizu J; Horio Y; Ueda R; Takahashi T; Mitsudomi T; Yatabe Y J Pathol; 2007 Jul; 212(3):287-94. PubMed ID: 17534846 [TBL] [Abstract][Full Text] [Related]
26. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case. Gow CH; Wu SG; Chang YL; Shih JY Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Hofman P; Ilie M; Hofman V; Roux S; Valent A; Bernheim A; Alifano M; Leroy-Ladurie F; Vaylet F; Rouquette I; Validire P; Beau-Faller M; Lacroix L; Soria JC; Fouret P Ann Oncol; 2012 Jul; 23(7):1738-43. PubMed ID: 22100693 [TBL] [Abstract][Full Text] [Related]
28. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183 [TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes of Resected Pure Ground-Glass, Heterogeneous Ground-Glass, and Part-Solid Pulmonary Nodules. Sun JD; Sugarbaker E; Byrne SC; Gagné A; Leo R; Swanson SJ; Hammer MM AJR Am J Roentgenol; 2024 May; 222(5):e2330504. PubMed ID: 38323785 [No Abstract] [Full Text] [Related]
30. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378 [TBL] [Abstract][Full Text] [Related]
31. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083 [TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. Chung JH; Choe G; Jheon S; Sung SW; Kim TJ; Lee KW; Lee JH; Lee CT J Thorac Oncol; 2009 Dec; 4(12):1490-5. PubMed ID: 19844187 [TBL] [Abstract][Full Text] [Related]
33. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486 [TBL] [Abstract][Full Text] [Related]
34. Morphological factors differentiating between early lung adenocarcinomas appearing as pure ground-glass nodules measuring ≤10 mm on thin-section computed tomography. Xiang W; Xing Y; Jiang S; Chen G; Mao H; Labh K; Jia X; Sun X Cancer Imaging; 2014 Nov; 14(1):33. PubMed ID: 25608623 [TBL] [Abstract][Full Text] [Related]
35. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866 [TBL] [Abstract][Full Text] [Related]
36. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756 [TBL] [Abstract][Full Text] [Related]
37. Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines. Ferretti GR; Busser B; de Fraipont F; Reymond E; McLeer-Florin A; Mescam-Mancini L; Moro-Sibilot D; Brambilla E; Lantuejoul S Lung Cancer; 2013 Oct; 82(1):69-75. PubMed ID: 23927885 [TBL] [Abstract][Full Text] [Related]
38. Natural history and clinical characteristics of multiple pulmonary nodules with ground glass opacity. Sato Y; Fujimoto D; Morimoto T; Uehara K; Nagata K; Sakanoue I; Hamakawa H; Takahashi Y; Imai Y; Tomii K Respirology; 2017 Nov; 22(8):1615-1621. PubMed ID: 28608997 [TBL] [Abstract][Full Text] [Related]
39. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936 [TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]